<DOC>
	<DOCNO>NCT02476942</DOCNO>
	<brief_summary>This non-interventional study prospectively collect detail , high-quality documentation bleeds , HRQoL , safety patient hemophilia A without FVIII inhibitor treat accord local routine clinical practice ( receive FVIII replacement bypass agent either episodic prophylactic treatment ) . Actual patient enrol routine clinical practice observational study .</brief_summary>
	<brief_title>A Prospective Study Collect High-Quality Documentation Bleeds , Health-Related Quality Life ( HRQoL ) , Safety Outcomes Patients With Hemophilia A Treated With Standard-of-Care Treatment</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Cohort A : Patients great equal ( &gt; /= ) 12 year age time inform consent Cohort A : Diagnosis congenital hemophilia A severity document history hightiter inhibitor ( , &gt; /= 5 Bethesda unit [ BU ] ) Cohort B : Pediatric patient less ( &lt; ) 12 year age Cohort B : Diagnosis congenital hemophilia A severity document history hightiter inhibitor ( , &gt; /=5 BU ) Cohort C : Patients &gt; /=12 year age Cohort C : Diagnosis congenital hemophilia A FVIII activity &lt; 1 percent ( % ) Cohort C : No prior history positive inhibitor FVIII Prior RO5534262 ( applicable patient agree prior RO5534262 preclude participation future investigational RO5534262 study ) Bleeding disorder congenital hemophilia A Ongoing ( plan study ) immune tolerance induction therapy FVIII FVIII prophylaxis currently/previously expose inhibitor Previous concomitant thromboembolic disease Known human immunodeficiency virus ( HIV ) infection cluster differentiation ( CD ) 4 count &lt; 200 cell per microliter ( cells/mcL )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>